Miriam represents debtors and creditors in complex restructuring matters, in and out of court. Outside of her restructuring practice, Miriam has experience representing pro bono clients in immigration and human rights matters.
Blue Owl Capital Invests up to $1.05 Billion in BridgeBio Pharma
January 17, 2024
Cooley advised Blue Owl Capital, a top asset manager redefining alternatives, on its strategic investment a $300 million royalty financing and a $450 million credit facility in BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers.